Sign Up

To receive our monthly eNews as well as event notices and other updates, just enter your email address.

   Please leave this field empty

Stay Connected

Take a moment to learn more about NYAM's activities and events.

NYAM to Partner on Major Global Research Initiative on Diabetic Retinopathy

View the full partnership statement

The New York Academy of Medicine (NYAM) is pleased to announce its collaboration with the International Federation on Ageing (IFA), International Diabetes Federation (IDF), and International Agency for the Prevention of Blindness (IABP) to assess the global awareness, treatment, and implications of diabetic retinopathy, a common and serious complication of diabetes. View the full partnership statement.

Across the course of the Global Reseach Initiative on Diabetic Retinopathy evidence on knowledge, policies, standards of care, and supportive services for retinopathy will be gathered across 40 countries in order to inform clinical practice and policy development to improve the prevention and management of this disease.

“Given the scale of the diabetes epidemic worldwide, and the devastating impacts of vision loss, we are very pleased to be part of this important collaboration, which has the potential to improve policy and practice globally,” said Dr. Linda Weiss, Director of the Center for Evaluation and Applied Research.

NYAM’s Center for Evaluation and Applied Research and the Center for Health Innovation are conducting the research, including surveys, interviews, literature reviews, and projections of disease burden, that will form the basis of the project reports, policy recommendations, and other resources to be developed through this collaboration.

“NYAM is uniquely positioned to conduct this type of important research related to the prevention and treatment of chronic diseases, such as diabetic retinopathy.  Focusing on individuals and their broader communities helps us translate the research into policy that reduces the global burden of disease and disability”, said Dr. David Siscovick, NYAM Senior Vice President for Research.

The study is funded by Bayer Pharma AG; Bayer will not be involved in analysis of study findings.

 Print   Subscribe


Posted on May 12, 2014

Gina Ravosa
Director of Marketing & Communications
The New York Academy of Medicine
1216 Fifth Avenue
New York, NY 10029
(212) 822-7285


More NYAM News Articles

NYAM's 21st Annual Gala

NYAM Featured Report

At a time when clinics and hospitals are struggling to care for high-need, high-cost patients who require social support and medical care, a new report from The New York Academy of Medicine highlights solutions pioneered by harm reduction programs.

View report»

View news story»

NYAM's Latest Publication

View all NYAM publications»

Powered by Blackbaud
nonprofit software